10:58 AM EDT, 04/03/2025 (MT Newswires) -- RxSight's ( RXST ) Q1 revenue shortfall and lower 2025 guidance raise concerns about slowing growth and potential market saturation for its light adjustable lenses, BofA Securities said in a note on Thursday.

The company preannounced Q1 revenue of $37.9 million, up 28% from a year earlier, but falling short of analysts' expectations of $39.6 million. RxSight ( RXST ) also reduced its 2025 revenue guidance range to $160 million to $175 million, a significant cut from its previous projection of $185 million to $197 million.

BofA highlighted that new light delivery device placements may not be generating the same level of incremental light adjustable lens sales as in previous years, which could signal a longer-term slowdown.

The firm also pointed to the wider guidance range as a sign of increased uncertainty about the remainder of the year, reflecting broader economic headwinds impacting the premium intraocular lens market.

BofA downgraded its rating on RxSight's ( RXST ) stock to underperform from buy and reduced the price objective to $22 from $36.

Price: 15.01, Change: -11.11, Percent Change: -42.53